ME02380B - Mikobakterijska antigena kompozicija - Google Patents

Mikobakterijska antigena kompozicija

Info

Publication number: ME02380B
Authority: ME; Montenegro
Prior art keywords: antigenic composition; mycobacterium; mycobacterium antigenic; composition; antigenic
Prior art date: 2010-12-14

Application number

MEP-2016-60A

Other languages

German (de)

English (en)

French (fr)

Inventor

Stephane Andre Georges Godart

Amina Laanan

Dominique Ingrid Lemoine

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-14

Filing date

2011-12-14

Publication date

2016-06-20

2011-12-14 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2016-06-20 Publication of ME02380B publication Critical patent/ME02380B/me

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Inorganic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Pathology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

MEP-2016-60A 2010-12-14 2011-12-14 Mikobakterijska antigena kompozicija ME02380B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42272310P	2010-12-14	2010-12-14
EP11799673.6A EP2651437B1 (en)	2010-12-14	2011-12-14	Mycobacterium antigenic composition
PCT/EP2011/072816 WO2012080369A1 (en)	2010-12-14	2011-12-14	Mycobacterium antigenic composition

Publications (1)

Publication Number	Publication Date
ME02380B true ME02380B (me)	2016-06-20

Family

ID=45346501

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2016-60A ME02380B (me)	2010-12-14	2011-12-14	Mikobakterijska antigena kompozicija

Country Status (32)

Country	Link
US (5)	US9352030B2 (me)
EP (4)	EP3593813A1 (me)
JP (2)	JP5951633B2 (me)
KR (3)	KR20140029376A (me)
CN (4)	CN103249431B (me)
AR (1)	AR084285A1 (me)
AU (2)	AU2011343367B2 (me)
BR (2)	BR112013014599A2 (me)
CA (2)	CA2819298A1 (me)
CO (2)	CO6751287A2 (me)
CY (1)	CY1122187T1 (me)
DK (3)	DK2651436T3 (me)
EA (2)	EA027504B1 (me)
ES (3)	ES2748651T3 (me)
HR (3)	HRP20160362T1 (me)
HU (3)	HUE045766T2 (me)
IL (2)	IL226450A0 (me)
LT (1)	LT3023106T (me)
ME (1)	ME02380B (me)
MX (2)	MX344280B (me)
MY (1)	MY161412A (me)
PL (3)	PL2651437T3 (me)
PT (2)	PT2651436E (me)
RS (1)	RS54687B1 (me)
SG (2)	SG190731A1 (me)
SI (3)	SI2651436T1 (me)
SM (1)	SMT201600118B (me)
TW (1)	TW201305192A (me)
UA (2)	UA110806C2 (me)
UY (1)	UY33802A (me)
WO (2)	WO2012080369A1 (me)
ZA (2)	ZA201304015B (me)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2524570T3 (es)	2005-04-29	2014-12-10	Glaxosmithkline Biologicals S.A.	Procedimiento de prevención o tratamiento de infección por M. tuberculosis
RS54687B1 (en) *	2010-12-14	2016-08-31	Glaxosmithkline Biologicals S.A.	COMPOSITION OF MYCOBACTERIAL ANTIGENS
WO2012093137A1 (en)	2011-01-04	2012-07-12	Archivel Farma, Sl	Liposome formulation suitable for treating or preventing tuberculosis
DK2802345T3 (en)	2012-01-12	2018-04-30	Archivel Farma Sl	MTB-C-VACCINE AGAINST ALLERGIC REACTIONS
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
GB201405921D0 (en)	2014-04-02	2014-05-14	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
ES2759260T3 (es)	2014-04-23	2020-05-08	Juno Therapeutics Inc	Métodos para aislar, cultivar y modificar genéticametne poblaciones de células inmunes para la terapia adoptiva
GB201513176D0 (en)	2015-07-27	2015-09-09	Glaxosmithkline Biolog Sa	Novel methods for inducing an immune response
GB201522068D0 (en)	2015-12-15	2016-01-27	Glaxosmithkline Biolog Sa	Dried composition
CN110035770B (zh)	2016-12-07	2023-06-16	葛兰素史密丝克莱恩生物有限公司	新方法
GB201621686D0 (en)	2016-12-20	2017-02-01	Glaxosmithkline Biologicals Sa	Novel methods for inducing an immune response
GB201707700D0 (en)	2017-05-12	2017-06-28	Glaxosmithkline Biologicals Sa	Dried composition
IE20190086A1 (en)	2017-05-30	2019-12-25	Glaxosmithkline Biologicals Sa	Novel methods for manufacturing an adjuvant
CA3083078A1 (en)	2017-12-01	2019-06-06	Glaxosmithkline Biologicals Sa	Saponin purification
RU2728976C2 (ru) *	2018-03-22	2020-08-03	Зули Холдингз, Лтд.	Липосомный состав и его получение
US20210292395A1 (en)	2018-07-31	2021-09-23	Glaxosmithkline Biologicals Sa	Antigen purification method
EP3886901A1 (en)	2018-11-29	2021-10-06	GlaxoSmithKline Biologicals S.A.	Methods for manufacturing an adjuvant
JP2022535091A (ja)	2019-06-05	2022-08-04	グラクソスミスクラインバイオロジカルズソシエテアノニム	サポニン精製
EP3777884A1 (en)	2019-08-15	2021-02-17	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
CA3092525A1 (en)	2019-09-09	2021-03-09	Glaxosmithkline Biologicals S.A.	Immunotherapeutic compositions
WO2021099982A1 (en)	2019-11-22	2021-05-27	Glaxosmithkline Biologicals Sa	Dosage and administration of a bacterial saccharide glycoconjugate vaccine
CN115485057A (zh)	2020-05-05	2022-12-16	葛兰素史克生物有限公司	微流体混合装置和使用方法
US20230234992A1 (en)	2020-06-05	2023-07-27	Glaxosmithkline Biologicals Sa	Modified betacoronavirus spike proteins
MX2023006769A (es)	2020-12-09	2023-08-18	Glaxosmithkline Biologicals Sa	Modificacion de saponinas.
CN114034860A (zh) *	2021-11-01	2022-02-11	宁夏大学	一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en)	2022-06-15	2023-12-21	Glaxosmithkline Biologicals Sa	Enzymatic modification of saponins
CN116120411B (zh) *	2022-12-07	2024-04-12	中国疾病预防控制中心传染病预防控制所	结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4436727A (en)	1982-05-26	1984-03-13	Ribi Immunochem Research, Inc.	Refined detoxified endotoxin product
US4866034A (en)	1982-05-26	1989-09-12	Ribi Immunochem Research Inc.	Refined detoxified endotoxin
US4877611A (en)	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
CA1331443C (en)	1987-05-29	1994-08-16	Charlotte A. Kensil	Saponin adjuvant
US5278302A (en)	1988-05-26	1994-01-11	University Patents, Inc.	Polynucleotide phosphorodithioates
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
ATE115862T1 (de)	1989-02-04	1995-01-15	Akzo Nobel Nv	Tocole als impfstoffadjuvans.
CZ289476B6 (cs)	1993-03-23	2002-01-16	Smithkline Beecham Biologicals (S.A.)	Očkovací přípravek a způsob jeho výroby
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
ATE420171T1 (de)	1994-07-15	2009-01-15	Univ Iowa Res Found	Immunomodulatorische oligonukleotide
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
HU225979B1 (en)	1995-09-01	2008-02-28	Corixa Corp	Compounds and methods for immunotherapy and diagnosis of tuberculosis
DE69636075D1 (de)	1995-09-01	2006-06-01	Corixa Corp	Verbindungen und verfahren zur diagnose von tuberkulose
US5666153A (en)	1995-10-03	1997-09-09	Virtual Shopping, Inc.	Retractable teleconferencing apparatus
GB9619613D0 (en)	1996-09-19	1996-10-30	Breed Automotive Tech	An inflatable restraint for a vehicle
EP0859366A1 (en)	1997-02-12	1998-08-19	STMicroelectronics S.r.l.	Associative memory device with optimized occupation, particularly for the recognition of words
NZ500028A (en) *	1997-04-08	2001-08-31	Merck & Co Inc	Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
US6764840B2 (en)	1997-05-08	2004-07-20	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en)	1997-05-08	2000-09-05	Ribi Immunochem Research, Inc.	Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en)	1997-05-08	2001-10-16	Corixa Corporation	Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en)	1997-12-24	1998-02-25	Smithkline Beecham Biolog	Vaccine
DE19803453A1 (de)	1998-01-30	1999-08-12	Boehringer Ingelheim Int	Vakzine
IL138809A0 (en)	1998-04-07	2001-10-31	Corixa Corp	Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same
AU746163B2 (en) *	1998-04-09	2002-04-18	Smithkline Beecham Biologicals (Sa)	Adjuvant compositions
US20040006242A1 (en)	1999-02-01	2004-01-08	Hawkins Lynn D.	Immunomodulatory compounds and method of use thereof
US6551600B2 (en)	1999-02-01	2003-04-22	Eisai Co., Ltd.	Immunological adjuvant compounds compositions and methods of use thereof
CA2386841A1 (en)	1999-10-07	2001-04-12	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
ATE526994T1 (de)	2000-06-20	2011-10-15	Corixa Corp	Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
SK288007B6 (sk)	2000-06-29	2012-10-02	Glaxosmithkline Biologicals S. A.	Multivalent vaccine composition, process for its producing, and its use
AU2003213118A1 (en) *	2002-02-15	2003-09-09	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en)	2004-05-21	2004-06-23	Glaxosmithkline Biolog Sa	Vaccines
ES2524570T3 (es)	2005-04-29	2014-12-10	Glaxosmithkline Biologicals S.A.	Procedimiento de prevención o tratamiento de infección por M. tuberculosis
WO2008140478A2 (en) *	2006-11-01	2008-11-20	Immport Therapeutics, Inc.	Compositions and methods for immunodominant antigens
SI2148697T1 (sl)	2007-05-24	2013-01-31	Glaxosmithkline Biologicals S.A.	Liofilizirani sestavek, ki vsebuje CpG in WT-1
NZ709704A (en) *	2007-11-30	2017-03-31	Abbvie Biotechnology Ltd	Protein formulations and methods of making same
KR100955470B1 (ko) *	2008-01-09	2010-04-30	대한민국(관리부서 질병관리본부장)	탄저 방어 항원의 제조 방법
US8409901B2 (en)	2008-03-11	2013-04-02	The Royal Institution For The Advancement Of Learning/Mcgill University	Low temperature wafer level processing for MEMS devices
GB0910046D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB0910045D0 (en) *	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB201008512D0 (en)	2010-05-21	2010-07-07	Health Prot Agency	Mycobacterial antigen composition
IT1400834B1 (it)	2010-07-07	2013-07-02	Aero Sekur S P A	Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
RS54687B1 (en)	2010-12-14	2016-08-31	Glaxosmithkline Biologicals S.A.	COMPOSITION OF MYCOBACTERIAL ANTIGENS
GB201400819D0 (en)	2014-01-17	2014-03-05	Sec Dep For Health The	Mycobacterial antigen composition

2011
- 2011-12-14 RS RS20160225A patent/RS54687B1/en unknown
- 2011-12-14 MY MYPI2013700989A patent/MY161412A/en unknown
- 2011-12-14 PL PL11799673T patent/PL2651437T3/pl unknown
- 2011-12-14 LT LT15201196T patent/LT3023106T/lt unknown
- 2011-12-14 PT PT117947788T patent/PT2651436E/pt unknown
- 2011-12-14 SG SG2013041793A patent/SG190731A1/en unknown
- 2011-12-14 MX MX2013006819A patent/MX344280B/es active IP Right Grant
- 2011-12-14 EP EP19188906.2A patent/EP3593813A1/en not_active Withdrawn
- 2011-12-14 EP EP11799673.6A patent/EP2651437B1/en active Active
- 2011-12-14 AU AU2011343367A patent/AU2011343367B2/en active Active
- 2011-12-14 US US13/993,736 patent/US9352030B2/en active Active
- 2011-12-14 SG SG2013041918A patent/SG190937A1/en unknown
- 2011-12-14 US US13/993,386 patent/US9730992B2/en active Active
- 2011-12-14 ES ES15201196T patent/ES2748651T3/es active Active
- 2011-12-14 EP EP11794778.8A patent/EP2651436B1/en active Active
- 2011-12-14 JP JP2013543775A patent/JP5951633B2/ja active Active
- 2011-12-14 AU AU2011343368A patent/AU2011343368C1/en not_active Ceased
- 2011-12-14 JP JP2013543776A patent/JP5951634B2/ja active Active
- 2011-12-14 UA UAA201306356A patent/UA110806C2/uk unknown
- 2011-12-14 AR ARP110104678A patent/AR084285A1/es unknown
- 2011-12-14 PL PL15201196T patent/PL3023106T3/pl unknown
- 2011-12-14 ME MEP-2016-60A patent/ME02380B/me unknown
- 2011-12-14 ES ES11794778.8T patent/ES2574403T3/es active Active
- 2011-12-14 EP EP15201196.1A patent/EP3023106B1/en active Active
- 2011-12-14 UA UAA201306355A patent/UA110118C2/uk unknown
- 2011-12-14 EA EA201390630A patent/EA027504B1/ru not_active IP Right Cessation
- 2011-12-14 HU HUE15201196A patent/HUE045766T2/hu unknown
- 2011-12-14 DK DK11794778.8T patent/DK2651436T3/da active
- 2011-12-14 EA EA201390631A patent/EA027920B1/ru not_active IP Right Cessation
- 2011-12-14 CN CN201180060222.7A patent/CN103249431B/zh active Active
- 2011-12-14 BR BR112013014599A patent/BR112013014599A2/pt not_active Application Discontinuation
- 2011-12-14 KR KR1020137018059A patent/KR20140029376A/ko not_active Application Discontinuation
- 2011-12-14 ES ES11799673.6T patent/ES2567190T3/es active Active
- 2011-12-14 WO PCT/EP2011/072816 patent/WO2012080369A1/en active Application Filing
- 2011-12-14 HU HUE11794778A patent/HUE028452T2/en unknown
- 2011-12-14 DK DK11799673.6T patent/DK2651437T3/en active
- 2011-12-14 SI SI201130859A patent/SI2651436T1/sl unknown
- 2011-12-14 HU HUE11799673A patent/HUE027932T2/en unknown
- 2011-12-14 CA CA2819298A patent/CA2819298A1/en not_active Abandoned
- 2011-12-14 SI SI201131805T patent/SI3023106T1/sl unknown
- 2011-12-14 DK DK15201196.1T patent/DK3023106T3/da active
- 2011-12-14 CN CN201710066847.3A patent/CN106822883A/zh active Pending
- 2011-12-14 SI SI201130787A patent/SI2651437T1/sl unknown
- 2011-12-14 PL PL11794778.8T patent/PL2651436T3/pl unknown
- 2011-12-14 PT PT152011961T patent/PT3023106T/pt unknown
- 2011-12-14 CN CN201610883668.4A patent/CN106822882A/zh active Pending
- 2011-12-14 TW TW100146325A patent/TW201305192A/zh unknown
- 2011-12-14 WO PCT/EP2011/072817 patent/WO2012080370A1/en active Application Filing
- 2011-12-14 KR KR1020137018060A patent/KR101951894B1/ko active IP Right Grant
- 2011-12-14 BR BR112013014598A patent/BR112013014598A2/pt not_active Application Discontinuation
- 2011-12-14 UY UY0001033802A patent/UY33802A/es not_active Application Discontinuation
- 2011-12-14 KR KR1020197004934A patent/KR20190022897A/ko not_active Application Discontinuation
- 2011-12-14 CA CA2819297A patent/CA2819297A1/en not_active Abandoned
- 2011-12-14 CN CN201180060489.6A patent/CN103260642B/zh active Active
- 2011-12-14 MX MX2013006818A patent/MX344706B/es active IP Right Grant
2013
- 2013-05-20 IL IL226450A patent/IL226450A0/en unknown
- 2013-05-20 IL IL226448A patent/IL226448A/en active IP Right Grant
- 2013-05-31 ZA ZA2013/04015A patent/ZA201304015B/en unknown
- 2013-05-31 ZA ZA2013/04014A patent/ZA201304014B/en unknown
- 2013-06-19 CO CO13146289A patent/CO6751287A2/es unknown
- 2013-06-19 CO CO13146307A patent/CO6751288A2/es unknown
2016
- 2016-04-08 HR HRP20160362TT patent/HRP20160362T1/hr unknown
- 2016-04-18 US US15/131,422 patent/US20160220656A1/en not_active Abandoned
- 2016-04-22 SM SM201600118T patent/SMT201600118B/it unknown
- 2016-06-06 HR HRP20160606TT patent/HRP20160606T1/hr unknown
2017
- 2017-07-06 US US15/643,084 patent/US10441648B2/en active Active
2019
- 2019-02-08 US US16/270,887 patent/US20190183998A1/en not_active Abandoned
- 2019-10-11 HR HRP20191843TT patent/HRP20191843T1/hr unknown
- 2019-10-18 CY CY20191101093T patent/CY1122187T1/el unknown

Also Published As

Publication number	Publication date
EP2651437B1 (en)	2016-02-10
JP5951633B2 (ja)	2016-07-13
IL226448A (en)	2017-09-28
UA110806C2 (uk)	2016-02-25
ZA201304015B (en)	2018-12-19
SI3023106T1 (sl)	2019-11-29
HRP20160362T1 (hr)	2016-05-06
HUE045766T2 (hu)	2020-01-28
HRP20191843T1 (hr)	2019-12-27
CN106822883A (zh)	2017-06-13
KR101951894B1 (ko)	2019-02-26
PT3023106T (pt)	2019-11-04
SI2651437T1 (sl)	2016-05-31
CO6751288A2 (es)	2013-09-16
CN103260642B (zh)	2018-03-16
SMT201600118B (it)	2016-07-01
US20160220656A1 (en)	2016-08-04
JP2014505036A (ja)	2014-02-27
EP3023106A1 (en)	2016-05-25
MX2013006819A (es)	2013-08-26
KR20140029376A (ko)	2014-03-10
PL2651437T3 (pl)	2016-07-29
DK2651436T3 (da)	2016-06-20
EP3593813A1 (en)	2020-01-15
ES2574403T3 (es)	2016-06-17
UY33802A (es)	2012-07-31
CN106822882A (zh)	2017-06-13
PL2651436T3 (pl)	2016-10-31
US20190183998A1 (en)	2019-06-20
US20130280289A1 (en)	2013-10-24
WO2012080370A1 (en)	2012-06-21
CO6751287A2 (es)	2013-09-16
EA027504B1 (ru)	2017-08-31
PL3023106T3 (pl)	2019-12-31
JP2013545783A (ja)	2013-12-26
AU2011343367B2 (en)	2015-05-21
MX2013006818A (es)	2013-08-26
MX344706B (es)	2017-01-03
US9730992B2 (en)	2017-08-15
JP5951634B2 (ja)	2016-07-13
BR112013014599A2 (pt)	2016-09-27
DK3023106T3 (da)	2019-09-30
HRP20160606T1 (hr)	2016-07-01
US9352030B2 (en)	2016-05-31
TW201305192A (zh)	2013-02-01
HUE027932T2 (en)	2016-11-28
EP2651436A1 (en)	2013-10-23
RS54687B1 (en)	2016-08-31
CN103249431B (zh)	2016-11-02
EA201390630A1 (ru)	2013-12-30
CN103260642A (zh)	2013-08-21
ES2748651T3 (es)	2020-03-17
CA2819297A1 (en)	2012-06-21
AR084285A1 (es)	2013-05-08
US10441648B2 (en)	2019-10-15
BR112013014598A2 (pt)	2017-09-19
US20130287809A1 (en)	2013-10-31
LT3023106T (lt)	2019-10-25
CY1122187T1 (el)	2020-11-25
MY161412A (en)	2017-04-14
UA110118C2 (uk)	2015-11-25
AU2011343367A1 (en)	2013-07-11
KR20130124525A (ko)	2013-11-14
MX344280B (es)	2016-12-09
ES2567190T3 (es)	2016-04-20
EP2651437A1 (en)	2013-10-23
CN103249431A (zh)	2013-08-14
AU2011343368B2 (en)	2015-08-20
SG190937A1 (en)	2013-07-31
IL226450A0 (en)	2013-07-31
PT2651436E (pt)	2016-06-08
ZA201304014B (en)	2017-04-26
EP3023106B1 (en)	2019-07-31
WO2012080369A1 (en)	2012-06-21
EA027920B1 (ru)	2017-09-29
SI2651436T1 (sl)	2016-07-29
AU2011343368C1 (en)	2015-12-24
EP2651436B1 (en)	2016-03-30
AU2011343368A1 (en)	2013-07-11
KR20190022897A (ko)	2019-03-06
DK2651437T3 (en)	2016-05-02
CA2819298A1 (en)	2012-06-21
EA201390631A1 (ru)	2014-11-28
US20180071378A1 (en)	2018-03-15
SG190731A1 (en)	2013-07-31
HUE028452T2 (en)	2016-12-28
IL226448A0 (en)	2013-07-31

Publication	Publication Date	Title
ZA201304015B (en)	2018-12-19	Mycobacterium antigenic composition
GB201003924D0 (en)	2010-04-21	Immunogenic composition
GB201002983D0 (en)	2010-04-07	Nutritinal composition
GB201006699D0 (en)	2010-06-09	Composition
ZA201208093B (en)	2013-06-26	Mycobacterial antigen composition
GB201015132D0 (en)	2010-10-27	Vaccine composition
GB201006178D0 (en)	2010-06-02	Composition
EP2609931A4 (en)	2014-06-04	IMMUNOGENIC COMPOSITION
GB201017048D0 (en)	2010-11-24	Composition
GB201016970D0 (en)	2010-11-24	Composition
GB201005927D0 (en)	2010-05-26	Improved composition
GB201007531D0 (en)	2010-06-23	Composition
GB201006214D0 (en)	2010-06-02	Composition
GB201006204D0 (en)	2010-06-02	Composition
GB201004717D0 (en)	2010-05-05	Composition
GB201010657D0 (en)	2010-08-11	Composition
GB201006175D0 (en)	2010-06-02	Composition
GB201006182D0 (en)	2010-06-02	Composition
GB201006012D0 (en)	2010-05-26	Composition
GB201002356D0 (en)	2010-03-31	Composition
GB201003918D0 (en)	2010-04-21	Immunogenic composition
GB201006369D0 (en)	2010-06-02	Polysiloxane composition
GB201006181D0 (en)	2010-06-02	Composition
GB201006215D0 (en)	2010-06-02	Composition
GB201003768D0 (en)	2010-04-21	Composition